The content on this site is intended for healthcare professionals only
Dr Sparano presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the TAILORx trial.
The results show that 70% of women with early HR / HER2- breast cancer could be spared chemotherapy, based on the results from a 21gene assay.
For more on these results, watch his interview with ecancer and read our news coverage here.
Slides from this presentation are available here.
Hormonal receptor positive breast cancer adjuvant and metastatic indications
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
